Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes

Area of Science:

• Endocrinology and Metabolism
• Cardiovascular Research
• Pharmacology

Background:

• Sodium-glucose cotransporter2 (SGLT2) inhibitors, like empagliflozin, are known to reduce cardiovascular risk in diabetic patients.
• The impact of SGLT2 inhibitors on high-density lipoprotein (HDL) cholesterol subclasses remains unclear, despite some increasing low-density lipoprotein (LDL) levels.
• Potential mechanisms involving compensatory lipid metabolism and weight reduction due to SGLT2 inhibition require further investigation.

Purpose of the Study:

• To investigate the effects of canagliflozin on lipoprotein fractions, specifically LDL and HDL subclasses.
• To elucidate the relationship between SGLT2 inhibition, lipid metabolism, and body weight changes.

Main Methods:

• A multicenter prospective study involving 22 patients with type 2 diabetes (HbA1c ≥ 7.0%).
• Participants received 100 mg of canagliflozin orally once daily for 12 weeks.
• High-performance liquid chromatography was used to analyze 20 lipoprotein fractions before and after treatment.

Main Results:

• Significant reductions in body weight (69.7 to 67.9 kg), systolic blood pressure (129.3 to 119.5 mm Hg), and HbA1c (8.5% to 7.4%) were observed.
• Cholesterol levels increased in very large HDL (G14, G15) and large HDL (G16) subclasses (P < .05).

Conclusions:

• Canagliflozin treatment resulted in decreased body weight and improved glycemic control.
• Increases in very large and large HDL subclasses were noted, suggesting a potentially favorable lipid profile modification.
• These beneficial alterations may contribute to the suppression of cardiovascular outcomes in patients with type 2 diabetes.